Browse > Article
http://dx.doi.org/10.22643/JRMP.2019.5.1.26

188Re Labeled liver therapeutic drugs for hepatic carcinoma (HCC)  

Seelam, Sudhakara Reddy (Department of Nuclear Medicine, Seoul National University College of Medicine)
Banka, Vinay Kumar (Department of Nuclear Medicine, Seoul National University College of Medicine)
Lee, Yun-Sang (Department of Nuclear Medicine, Seoul National University College of Medicine)
Jeong, Jae Min (Department of Nuclear Medicine, Seoul National University College of Medicine)
Publication Information
Journal of Radiopharmaceuticals and Molecular Probes / v.5, no.1, 2019 , pp. 26-35 More about this Journal
Abstract
$^{188}Re$ is one of the most readily available generator derived and useful radionuclides for therapy emitting ${\beta}^-$ particles (2.12 MeV, 71.1% and 1.965 MeV, 25.6%) and imageable gammas (155 keV, 15.1%). The $^{188}W/^{188}Re$ generator is an ideal source for the long term (4-6 months) continuous availability of no carrier added (NCA) $^{188}Re$ suitable for the preparation of radiopharmaceuticals for radionuclide therapy. Rhenium-188 has been used for the preparation of therapeutic radiopharmaceuticals for the management of diseases such as bone metastasis, rheumatoid arthritis and primary cancers. Several early phase clinical studies using radiopharmaceuticals based on $^{188}Re$ -labeled phosphonates, antibodies, peptides, lipiodol and particulates have been reported. In this review, we addressed the current development status of $^{188}Re$ radiopharmaceuticals for liver cancer therapy and their applications.
Keywords
$^{188}Re$; Rhenium; Hepatic Carcinoma; Lipiodol; $N_2S_2$; HDD; TDD; HTDD;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Jeong JM, Kim YJ, Lee YS, Ko JI, Son M, Lee DS, et al. Lipiodol solution of a lipophilic agent, $^{(188)}Re$-TDD, for the treatment of liver cancer. Nucl Med Biol 2001;28(2):197-204.   DOI
2 Lee YS, Jeong JM, Kim YJ, Chang YS, Lee HJ, Son M, et al. Development of acetylated HDD kit for preparation of $^{188}Re$-HDD/lipiodol. Appl Radiat Isot 2007;65(1):64-69.   DOI
3 Nakakuma K, Tashiro S, Hiraoka T, Uemura K, Konno T, Miyauchi Y, et al. Studies on anticancer treatment with an oily anticancer drug injected into the ligated feeding hepatic artery for liver cancer. Cancer 1983;52(12):2193-2200.   DOI
4 Paeng JC, Jeong JM, Yoon CJ, Lee YS, Suh YG, Chung JW, et al. Lipiodol solution of $^{188}Re$-HDD as a new therapeutic agent for transhepatic arterial embolization in liver cancer: preclinical study in a rabbit liver cancer model. J Nucl Med 2003;44(12):2033-2038.
5 Madsen MT, Park CH, Thakur ML. Dosimetry of Iodine-131 Ethiodol in the Treatment of Hepatoma. J Nucl Med 1988;29(6):1038-1044.
6 Nakajo M, Kobayashi H, Shimabukuro K, Shirono K, Sakata H, Taguchi M, et al. Biodistribution and in vivo kinetics of iodine-131 lipiodol infused via the hepatic artery of patients with hepatic cancer. J Nucl Med 1988;29(6):1066-1077.
7 Turner JH, Claringbold PG, Klemp PF, Cameron PJ, Martindale AA, Glancy RJ, et al. $^{166}Ho$-microsphere liver radiotherapy: a preclinical SPECT dosimetry study in the pig. Nucl Med Comm 1994;15(7):545-553.   DOI
8 Wang SJ, Lin WY, Chen MN, Hsieh BT, Shen LH, Tsai ZT, et al. Biodistribution of rhenium-$^{188}Lipiodol$ infused via the hepatic artery of rats with hepatic tumours. Eur J Nucl Med 1996;23(1):13-17.   DOI
9 Wang SJ, Lin WY, Lui WY, Chen MN, Tsai ZT, Ting G. Hepatic artery injection of Yttrium-90-lipiodol: biodistribution in rats with hepatoma. J Nucl Med 1996;37(2):332-335.
10 Park CH, Suh JH, Yoo HS, Lee JT, Kim DI, Lee KS. Iodine-131-labeled lipiodol retention within hepatic cavernous hemangioma. Radiology 1987;163(1):283-284.   DOI
11 Raoul JL, Guyader D, Bretagne JF, Heautot JF, Duvauferrier R, Bourguet P, et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of $^{131}I$-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997;26(5):1156-1161.   DOI
12 Yoo HS, Suh JH, Lee JT, Kim DI, Park CY, Kim BS, et al. Therapeutic Feasibility Study and Clinical Trial of Intrahepatic $^{131}I$-Lipiodol on Patients with Hepatocellular Carcinoma. Korean J of Nucl Med 1986;20(2):61-71.
13 Lee YS, Jeong JM, Kim YJ, Chung JW, Park JH, Suh YG, et al. Synthesis of $^{188}Re$-labelled long chain alkyl diaminedithiol for therapy of liver cancer. Nucl Med Comm 2002;23(3):237-242.   DOI
14 Paeng JC, Jeong JM, Yoon CJ, Lee Y-S, Suh Y-G, Chung JW, et al. Lipiodol Solution of $^{188}Re$-HDD as a New Therapeutic Agent for Transhepatic Arterial Embolization in Liver Cancer: Preclinical Study in a Rabbit Liver Cancer Model. J Nucl Med 2003;44(12):2033-2038.
15 Banka VK, Moon S-H, Jeong JM, Seelam SR, Lee Y-S, Kim YJ, et al. Development of 4-hexadecyl-4, 7-diaza-1, 10-decanedithiol (HDD) kit for the preparation of the liver cancer therapeutic agent Re-$^{188}-HDD$/lipiodol. Nucl Med Biol 2015;42(3):317-322.   DOI
16 Gallicchio R, Nardelli A, Mainenti P, Nappi A, Capacchione D, Simeon V, et al. Therapeutic Strategies in HCC: Radiation Modalities. BioMed Research International 2016;2016:11.
17 Kumar A, Bal C, Srivastava DN, Thulkar SP, Sharma S, Acharya SK, et al. Management of multiple intrahepatic recurrences after radiofrequency ablation of hepatocellular carcinoma with rhenium-188-HDD$-lipiodol. European J of gastroenterology & hepatology 2006;18(2):219-223.   DOI
18 Chua TC, Chu F, Butler SP, Quinn RJ, Glenn D, Liauw W, et al. Intra-arterial iodine-131-lipiodol for unresectable hepatocellular carcinoma. Cancer 2010;116(17):4069-4077.   DOI
19 Kim Y, Jeong J, Kim S, Lee D, Chung J, Lee M, et al.. Rhenium-188-sulfur colloid suspended in Lipiodol: a capillary-blocking radiopharmaceutical for targeting liver cancer. J Nucl Med 1998;39:S51
20 Kumar A, Bal C, Srivastava DN, Acharya SK, Thulkar SP, Sharma S, et al. Transarterial radionuclide therapy with Re-188-HDD-lipiodol in case of unresectable hepatocellular carcinoma with extensive portal vein thrombosis. European J of Radiology Extra 2005;56(2):55-59.   DOI
21 Kumar A, Srivastava DN, Chau TT, Long HD, Bal C, Chandra P, et al. Inoperable hepatocellular carcinoma: transarterial $^{188}Re$ HDD-labeled iodized oil for treatment--prospective multicenter clinical trial. Radiology 2007;243(2):509-519.   DOI
22 Lambert B, Bacher K, De Keukeleire K, Smeets P, Colle I, Jeong JM, et al. $^{188}Re$-HDD/lipiodol for treatment of hepatocellular carcinoma: a feasibility study in patients with advanced cirrhosis. J Nucl Med 2005;46(8):1326-1332.
23 Lambert B, Bacher K, Defreyne L, Van Vlierberghe H, Jeong JM, Wang RF, et al. $^{(188)}Re$-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study. Eur J Nucl Med Mol Imaging 2006;33(3):344-352.   DOI
24 Boschi A, Bolzati C, Uccelli L, Duatti A. High-yield synthesis of the terminal $^{188}Re{\equiv}N$ multiple bond from generator-produced $[^{188}ReO_4]^-$. Nucl Med Biol 2003;30(4):381-387.   DOI
25 Luo T-Y, Hsieh B-T, Wang S-J, Lin W-Y, Lee T-W, Shen L-H, et al. Preparation and biodistribution of rhenium-188 ECD/Lipiodol in rats following hepatic arterial injection. Nucl Med Biol 2004;31(5):671-677.   DOI
26 Garin E, Noiret N, Malbert C, Lepareur N, Roucoux A, Caulet-Maugendre S, et al. Development and biodistribution of $^{188}Re$-SSS lipiodol following injection into the hepatic artery of healthy pigs. Eur J Nucl Med Mol Imaging 2004;31(4):542-546.   DOI
27 Garin E, Rakotonirina H, Lejeune F, Denizot B, Roux J, Noiret N, et al. Effect of a $^{188}Re$-SSS lipiodol/$^{131}I$-lipiodol mixture, $^{188}Re$-SSS lipiodol alone or $^{131}I$-lipiodol alone on the survival of rats with hepatocellular carcinoma. Nucl Med Comm 2006;27(4):363-369.   DOI
28 Bernal P, Raoul JL, Vidmar G, Sereegotov E, Sundram FX, Kumar A, et al. Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study. International J of Radiation Oncology, Biology, Physics 2007;69(5):1448-1455.   DOI
29 Sundram F, Chau TC, Onkhuudai P, Bernal P, Padhy AK. Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2004;31(2):250-257.   DOI
30 Boschi A, Uccelli L, Duatti A, Colamussi P, Cittanti C, Filice A, et al. A kit formulation for the preparation of $^{188}Re$-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma. Nucl Med Comm 2004;25(7):691-699.   DOI
31 Banka VK, Moon SH, Jeong JM, Seelam SR, Lee YS, Kim YJ, et al. Development of 4-hexadecyl-4,7-diaza-1,10-decanedithiol (HDD) kit for the preparation of the liver cancer therapeutic agent Re-188-HDD/lipiodol. Nucl Med Biol 2015;42(3):317-322.   DOI
32 Uccelli L, Pasquali M, Boschi A, Giganti M, Duatti A. Automated preparation of Re-188 lipiodol for the treatment of hepatocellular carcinoma. Nucl Med Biol 2011;38(2):207-213.   DOI
33 Guhlke S, Beets AL, Oetjen K, Mirzadeh S, Biersack HJ, Knapp FF, Jr. Simple new method for effective concentration of $^{188}Re$ solutions from alumina-based $^{188}W$-$^{188}Re$ generator. J Nucl Med 2000;41(7):1271-1278.
34 Jeong JM, Knapp Jr FF. Use of the Oak Ridge National Laboratory Tungsten-188/Rhenium-188 Generator for Preparation of the Rhenium-188 HDD/Lipiodol Complex for Trans-Arterial Liver Cancer Therapy. Seminars in Nucl Med 2008;38(2):S19-S29.   DOI
35 Sarkar SK, Venkatesh M, Ramamoorthy N. Evaluation of two methods for concentrating perrhenate ($^{188}Re$) eluates obtained from $^{188}W$-$^{188}Re$ generator. Appl Radiat Isot 2009;67(2):234-239.   DOI
36 Thieme S, Agostini S, Bergmann R, Pietzsch J, Pietzsch H-J, Carta D, et al. Synthesis, characterization and biological evaluation of [$^{188}Re$(N)(cys-)(PNP)]+/0 mixed-ligand complexes as prototypes for the development of $^{188}Re$(N)-based target-specific radiopharmaceuticals. Nucl Med Biol 2011;38(3):399-415.   DOI